File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study

TitleThe efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study
Authors
Issue Date2000
PublisherSpringer New York LLC. The Journal's web site is located at http://link.springer.de/link/service/journals/00223
Citation
Calcified Tissue International, 2000, v. 67 n. 4, p. 286-290 How to Cite?
AbstractOsteoporosis is a growing health problem in Asian women and it is expected that half of the world's hip fractures will occur in Asia in 50 years' time. As the use of hormonal replacement therapy (HRT) is extremely low in postmenopausal Asian women, nonhormonal agents will be more acceptable for the treatment and prevention of osteoporosis. The efficacy, tolerability, and acceptability of alendronate, an amino-bisphosphonate, for Asian women was evaluated in 70 osteoporotic southern Chinese women in a prospective, randomized, double-blind study. The subjects were randomized to receive either alendronate 10 mg daily or placebo, plus calcium supplementation 500 mg daily. The baseline L 1-4 and hip bone mineral density (BMD) were similar between both groups. At the end of 1 year, there was an increase of 5.8% in the lumbar spine BMD and 3.4% at the total hip with alendronate treatment when compared with baseline values (P < 0.001). Alendronate treatment for 1 year resulted in significant improvement in BMD at all sites measured when compared with placebo. There was also marked reduction in serum alkaline phosphatase (ALP) and urinary n-telopeptide (NTx) in the alendronate group when compared with the placebo group (ALP 25% versus 2%, NTx 75% versus 14%, both P < 0.005). The changes in ALP and NTx at 6 and 12 months correlated with the change in BMD at all sites measured at 1 year (P all <0.05). Alendronate was well tolerated and accepted, although two cases of gastric ulcer were reported. We conclude that alendronate is an effective and well-accepted agent for the treatment of osteoporosis in Asian women.
Persistent Identifierhttp://hdl.handle.net/10722/162379
ISSN
2015 Impact Factor: 3.052
2015 SCImago Journal Rankings: 1.166
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_US
dc.contributor.authorYeung, SSCen_US
dc.contributor.authorChu, LWen_US
dc.date.accessioned2012-09-05T05:19:24Z-
dc.date.available2012-09-05T05:19:24Z-
dc.date.issued2000en_US
dc.identifier.citationCalcified Tissue International, 2000, v. 67 n. 4, p. 286-290en_US
dc.identifier.issn0171-967Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162379-
dc.description.abstractOsteoporosis is a growing health problem in Asian women and it is expected that half of the world's hip fractures will occur in Asia in 50 years' time. As the use of hormonal replacement therapy (HRT) is extremely low in postmenopausal Asian women, nonhormonal agents will be more acceptable for the treatment and prevention of osteoporosis. The efficacy, tolerability, and acceptability of alendronate, an amino-bisphosphonate, for Asian women was evaluated in 70 osteoporotic southern Chinese women in a prospective, randomized, double-blind study. The subjects were randomized to receive either alendronate 10 mg daily or placebo, plus calcium supplementation 500 mg daily. The baseline L 1-4 and hip bone mineral density (BMD) were similar between both groups. At the end of 1 year, there was an increase of 5.8% in the lumbar spine BMD and 3.4% at the total hip with alendronate treatment when compared with baseline values (P < 0.001). Alendronate treatment for 1 year resulted in significant improvement in BMD at all sites measured when compared with placebo. There was also marked reduction in serum alkaline phosphatase (ALP) and urinary n-telopeptide (NTx) in the alendronate group when compared with the placebo group (ALP 25% versus 2%, NTx 75% versus 14%, both P < 0.005). The changes in ALP and NTx at 6 and 12 months correlated with the change in BMD at all sites measured at 1 year (P all <0.05). Alendronate was well tolerated and accepted, although two cases of gastric ulcer were reported. We conclude that alendronate is an effective and well-accepted agent for the treatment of osteoporosis in Asian women.en_US
dc.languageengen_US
dc.publisherSpringer New York LLC. The Journal's web site is located at http://link.springer.de/link/service/journals/00223en_US
dc.relation.ispartofCalcified Tissue Internationalen_US
dc.subject.meshAbsorptiometry, Photonen_US
dc.subject.meshAgeden_US
dc.subject.meshAlendronate - Therapeutic Useen_US
dc.subject.meshAlkaline Phosphatase - Blooden_US
dc.subject.meshAsian Continental Ancestry Groupen_US
dc.subject.meshBone Density - Drug Effectsen_US
dc.subject.meshChina - Epidemiologyen_US
dc.subject.meshCollagen - Urineen_US
dc.subject.meshCollagen Type Ien_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshFemuren_US
dc.subject.meshHumansen_US
dc.subject.meshLumbar Vertebraeen_US
dc.subject.meshOsteoporosis, Postmenopausal - Drug Therapy - Ethnology - Metabolismen_US
dc.subject.meshPelvic Bonesen_US
dc.subject.meshPeptides - Urineen_US
dc.subject.meshPlacebosen_US
dc.subject.meshProspective Studiesen_US
dc.titleThe efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s002230001142en_US
dc.identifier.pmid11000341-
dc.identifier.scopuseid_2-s2.0-0033796017en_US
dc.identifier.hkuros57616-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033796017&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume67en_US
dc.identifier.issue4en_US
dc.identifier.spage286en_US
dc.identifier.epage290en_US
dc.identifier.isiWOS:000089360200002-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US
dc.identifier.scopusauthoridYeung, SSC=7102767673en_US
dc.identifier.scopusauthoridChu, LW=7202236665en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats